LMY-920 – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 16 Aug 2022 09:39:58 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png LMY-920 – VJRegenMed https://mirror.vjregenmed.com 32 32 Advances in allogeneic γδ T cells https://mirror.vjregenmed.com/video/vt5sk0mooqi-advances-in-allogeneic-%ce%b3%ce%b4-t-cells/ Tue, 22 Feb 2022 15:00:55 +0000 http://13.40.107.223/video/vt5sk0mooqi-advances-in-allogeneic-%ce%b3%ce%b4-t-cells/ Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, discusses the development of allogeneic gamma delta (γδ) T cells. Whilst there has previously been a focus on autologous therapies such as LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, current attention is directed towards allogeneic therapies. The emergence of γδ T cells have been beneficial as they do not cause graft versus host disease (GvHD) and are already HLA matched between donor and patient. Dr Liter additionally highlights a proprietary Tc Buster Transposon system that enables expansion of the Vδ1 and Vδ2 subtypes of γδ T cells. This interview took place at Advanced Therapies Week 2022.

]]>
LMY-920 in non-Hodgkin lymphoma https://mirror.vjregenmed.com/video/jrdkliwleru-lmy-920-in-non-hodgkin-lymphoma/ Mon, 14 Feb 2022 17:40:19 +0000 http://13.40.107.223/video/jrdkliwleru-lmy-920-in-non-hodgkin-lymphoma/ Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.

]]>